- HOME
- >
- Corporate Guide
- >
- Corporate History
Corporate History
As of March 31, 2022
| 1925 | Established Takara Shuzo Co., Ltd |
|---|---|
| 1970 | Launched the Central Research Laboratories in the city of Otsu, Shiga |
| 1973 | Developed and commercialized an artificial cultivation method for Bunashimeji mushrooms |
| 1979 | Commenced sales of the first domestically produced restriction enzymes as reagents for genetic engineering research Entered Biomedical Business  |
| 1988 | Acquired exclusive distribution rights in Japan for a gene amplification system using PCR technology |
| 1993 | Obtained worldwide PCR-related patent licenses to manufacture PCR products |
| 1993 | Established Takara Biotechnology (Dalian) Co., Ltd. in China, in order to manufacture life science research reagents |
| 1995 | Established Takara Biomedical Europe S.A.(currently Takara Bio Europe S.A.S) in Paris, France, in order to sell life science research reagents |
| 1995 | Developed the RetroNectin® Method for highly-efficient retrovial transduction in hematopoietic stem cells |
| 1995 | Established Bohan Biomedical Inc.(currently Takara Korea Biomedical Inc.) in Seoul, Korea |
| 2000 | Established DRAGON GENOMICS Co., LTD. (merged to Takara Bio in 2002) Launched full-scale genetic analysis services  |
| 2001 | Established Mizuho Norin Co., Ltd. (transferred to YUKIGUNI MAITAKE CO., LTD. in 2019) |
| 2002 | Established Takara Bio Inc. in the city of Otsu, Shiga, split off from Takara Shuzo, Co., Ltd. |
| 2004 | Established Takara Biomedical Technology (Beijing) Co., Ltd. in China |
| 2004 | Listed on the TSE Mothers Index |
| 2005 | Acquired U.S.-based Clontech Laboratories, Inc. (currently Takara Bio USA, Inc.) |
| 2007 | Established KINOKO CENTER KIN INC. in Okinawa (transferred to YUKIGUNI MAITAKE CO., LTD. in 2019) |
| 2011 | Established DSS Takara Bio India Pvt. Ltd. in New Delhi, India |
| 2014 | Acquired Cellectis AB (currently Takara Bio Europe AB) in Göteborg, Sweden |
| 2014 | Launched the Center for Gene and Cell Processing Started CDMO business providing manufacturing and development support services for regenerative medicine products, etc.  |
| 2015 | Launched new research facility in Kusatsu, Shiga Headquarters functions relocated  |
| 2016 | Changed listing to the First Section of the TSE |
| 2017 | Acquired Rubicon Genomics, Inc. by wholly-owned subsidiary Takara Bio USA Holdings, Inc., thereafter merged to Takara Bio USA, Inc. |
| 2017 | Acquired Wafergen Bio-systems, Inc. by wholly-owned subsidiary Takara Bio USA Holdings, Inc., thereafter merged to Takara Bio USA, Inc. |
| 2018 | Designated NY-ESO-1 siTCRTM as a product under the "SAKIGAKE Designation System", thereafter succeeded to Otsuka Pharmaceutical Co., Ltd. |
| 2018 | Executed exclusive license agreement relating to NY-ESO-1 siTCRTM and CD19 CAR gene therapy products with Otsuka Pharmaceutical Co., Ltd. |
| 2019 | Transferred the AgriBio Business |
| 2020 | Launched the Center for Gene and Cell Processing II |
| 2020 | Launched Takara SARS-CoV-2 Direct PCR kit, an in vitro diagnostic |
| 2020 | NY-ESO-1 siTCRTM designated as an Orphan Regenerative Medicine |
| 2021 | Established Takara Bio UK Ltd. |
| 2021 | Takara Bio USA Inc. relocated its headguarters to San Jose, California, USA |
| 2022 | Changed to the Prime Market of the Tokyo Stock Exchange |